Colossal Biosciences Raises Funding at $20B-$30B Valuation
Key Points
- Colossal Biosciences is negotiating new funding at a $20 billion to $30 billion valuation, nearly triple its previous $10.2 billion valuation.
- The company has started generating revenue through conservation technology partnerships with the U.S. government and UAE, which invested $60 million.
- Colossal has spun out three companies including Form Bio ($30 million funded) and Astromech (valued at $2 billion in March), diversifying revenue beyond de-extinction projects.
From De-Extinction to Diversified Revenue Streams
Beyond its core de-extinction efforts targeting woolly mammoths and dodo birds, Colossal has established a corporate structure generating substantial value through subsidiary companies. The company spun out Breaking, a plastics breakdown technology company; Form Bio, a computational biology platform that has secured $30 million in funding; and Astromech, an AI-driven predictive modeling company focused on biology and life sciences that achieved a $2 billion valuation in March.
Read Next
Meta Reports Q2 Earnings Amid AI Investment Concerns
7 days ago
Nvidia Launches Cybersecurity Initiative for Open-Source AI Defense
8 days ago
Lamm has indicated the company plans to spin off its artificial animal womb technology, which could have applications for human fertility treatment. He told Rolling Stone in May that this technology is expected to be ready next year, opening another potential revenue avenue distinct from conservation or de-extinction applications.
A long-term revenue model for Colossal's de-extinction efforts involves biodiversity credits—market-based mechanisms similar to carbon credits that could be generated when extinct species are successfully reintroduced to their native habitats. This represents a novel approach to monetizing conservation outcomes, though it remains contingent on successfully completing the biological and ecological challenges associated with species resurrection and reintroduction.
Related coverage: Meta Reports Q2 Earnings Amid AI Investment Concerns
The company's valuation trajectory reflects broader investor appetite for deep-tech ventures. The fundraising effort coincides with significant momentum in longevity technology, alternative energy, and other frontier life sciences sectors attracting substantial venture capital.
Colossal's three-year jump from $10.2 billion to a $20-$30 billion valuation range represents one of the steepest increases among biotech startups of its age, particularly notable given that the company's primary marketed achievement—de-extinction of Ice Age megafauna—remains largely in the research phase. The valuation increase instead reflects investor confidence in the underlying technology platforms Colossal has developed and its ability to commercialize conservation and synthetic biology tools across multiple applications.
The company's structure as both a de-extinction venture and an incubator for spinoff companies mirrors a model more commonly associated with technology accelerators than traditional biotech firms, allowing it to capture value across multiple emerging sectors simultaneously.
Why this matters: If you're tracking deep-tech valuations or considering investments in life sciences ventures, Colossal's funding round signals investor confidence in synthetic biology and conservation technology is reaching institutional scale. The company's success in generating revenue from government and sovereign wealth partnerships, rather than relying solely on speculative de-extinction outcomes, demonstrates that underlying technologies may have commercial viability independent of bringing back extinct species. For those interested in biodiversity, this suggests private capital is increasingly willing to fund large-scale conservation interventions.
What This Means
Colossal's valuation trajectory suggests the de-extinction sector is attracting mainstream venture and institutional capital despite biological uncertainties. If successful in closing this round at the upper valuation range, Colossal could establish a template for commercializing frontier biotech through spinout diversification. The company's focus on government partnerships and spinout valuations indicates the real revenue driver may be underlying synthetic biology platforms rather than de-extinction itself, potentially shifting investor focus toward tangible near-term applications.
Sources: AP, Reuters, ESPN, Bloomberg, BBC and other international news outlets.
Disclaimer: This article is for informational purposes only. Content is based on publicly available news sources.
NewsOracle Editorial
The NewsOracle Tech Desk covers breaking technology news including AI, Apple, Google, Tesla, Meta, OpenAI and product launches.
Latest coverage: Colossal Biosciences
